logo-loader

Four high-flying growth companies set to take the stage at Proactive's biggest virtual investor forum to date

Last updated: 16:15 07 Dec 2020 EST, First published: 10:00 04 Dec 2020 EST

Algernon Pharmaceuticals Inc. -

Proactive’s first virtual event for December brings together a selection exciting growth companies from different sectors ranging from data privacy to biotechnology.

Each has its own unique story and may be embracing different fields but what they have in common is enormous potential.

Sign on to join Proactive's One2One virtual investor forum on December 8 at 1:30pm ET and hear executives from these four high performing companies.

SIGN UP: Proactive One2One December 8

KWESST: Developing 'freakishly smart' military technology

Presenting at the event is KWESST Micro Systems Inc (CVE:KWE) executive chairman David Luxton, part of the team behind the military technology company that’s been dubbed “freakishly smart” thanks to its signature Tactical and Situational Control System (TASCS), which streams real-time awareness and targeting information from any source (including drones) directly to a soldier’s smart device and weapon.

The Ottawa-based company boasts a diversified product line, springing from a single core technology — its proprietary Micro Integrated Sensor Systems Technology (MISST) — which involves ultra-miniaturization and integration of sensors, software, optics, ballistics, machine learning and artificial intelligence that boosts mission capability.

An OTC listing is in the works for the Canadian company to open up its investor base south of the border, where its technology is gaining the attention of US military customers.

CLICK HERE TO SIGN UP

Lineage Cell Therapeutics: The clinical-stage biotechnology company flying under the radar

California-based Lineage Cell Therapeutics is a clinical-stage biotechnology company that is developing cell therapies for unmet medical needs, particularly in the areas of eye disease, spinal cord injuries and cancer immuno-therapy.

With three clinical-stage assets, the $140 million market capitalization looks anomalous and suggests that Lineage is flying well below the radar.

The group’s 2020 objectives involve ongoing manufacturing activity rather than enrollment milestones, with a lead program to address a slow, progressive disease. CEO Brian Culley recently told shareholders that he believes the firm’s operational clinical sites gives it an advantage.

CLICK HERE TO SIGN UP

Killi: Empowering users to take control of their data

Killi Ltd (CVE:MYID) (OTCMKTS:MYIDF) works to help consumers take back control of their identity from those who have been using it without their consent. Using Killi, consumers can opt in and select specific pieces of personal information that they would like to share with brands in exchange for compensation.

The company’s software lets users make money from their data through data sharing, surveys, offers and watching videos on Android.

"The conversation around the use of consumer data by Big Tech has reached a boiling point in 2020, as antitrust, legal and privacy concerns continue to grow in prominence," CEO Neil Sweeney told shareholders recently.

Killi is available in six countries on iOS and Android, and the app pays its users weekly.

CLICK HERE TO SIGN UP

Algernon Pharmaceuticals: The biotech company stepping up to develop a potential coronavirus treatment

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:BTHCF) is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD).

The company identifies drugs that are used to treat one condition but repurposes them for different treatments.

Most recently the company is focusing its efforts on repurposing ifenprodil (NP-120) as a potential coronavirus (COVID-19) treatment. Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively.

CLICK HERE TO SIGN UP

About the event:

Join an audience of astute high net worth investors, fund managers, private client brokers and analysts.

We look beyond the numbers and meet the people creating the value for shareholders.

The format:

Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story.

You can watch the event afterwards on Proactive's YouTube channel.

CLICK HERE TO SIGN UP

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

5 hours, 20 minutes ago